AnaptysBio to Present at the 2020 Cantor Global Virtual Healthcare Conference
September 11, 2020 16:05 ET
|
AnaptysBio, Inc.
SAN DIEGO, Sept. 11, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical...
AnaptysBio Announces Second Quarter 2020 Financial Results and Provides Pipeline Updates
August 10, 2020 08:05 ET
|
AnaptysBio, Inc.
Interim 8-Week Top-Line Data From Etokimab ECLIPSE Phase 2 Trial in Chronic Rhinosinusitis with Nasal Polyps Did Not Demonstrate Statistical Significance For Either Q4W or Q8W Versus Placebo; Company...
AnaptysBio Reports Top-Line Data from Interim Analysis of ECLIPSE Phase 2 Clinical Trial of Etokimab in Chronic Rhinosinusitis with Nasal Polyps
August 10, 2020 08:00 ET
|
AnaptysBio, Inc.
Etokimab q4w and q8w treatment arms failed to achieve NPS and SNOT-22 statistical significance over placebo at this week 8 interim analysisSecondary analyses demonstrated NPS and blood eosinophil...
AnaptysBio to Present at The 2020 Wedbush PacGrow Healthcare Conference
August 05, 2020 16:05 ET
|
AnaptysBio, Inc.
SAN DIEGO, Aug. 05, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical...
AnaptysBio Appoints Dr. Paul F. Lizzul As Chief Medical Officer
July 31, 2020 08:30 ET
|
AnaptysBio, Inc.
SAN DIEGO, July 31, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune...
AnaptysBio Expands Executive Leadership Team
July 15, 2020 08:30 ET
|
AnaptysBio, Inc.
SAN DIEGO, July 15, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune...
AnaptysBio Announces Orphan Drug Designation of Imsidolimab For Treatment of Generalized Pustular Psoriasis
July 08, 2020 16:05 ET
|
AnaptysBio, Inc.
Additional Data and Regulatory Strategy Update From Generalized Pustular Psoriasis (GPP) Phase 2 GALLOP Trial Anticipated During H2 2020Palmoplantar pustulosis (PPP) Phase 2 POPLAR Trial Top-Line Data...
AnaptysBio Announces First Quarter 2020 Financial Results and Provides Pipeline Updates
May 06, 2020 16:05 ET
|
AnaptysBio, Inc.
Interim Top-Line Data From Etokimab ECLIPSE Phase 2 Trial in Chronic Rhinosinusitis with Nasal Polyps Anticipated in Third Quarter of 2020, Decided to Over-Enroll Trial Due to COVID-19 Additional...
AnaptysBio Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Pipeline Updates
March 02, 2020 08:45 ET
|
AnaptysBio, Inc.
Interim Top-Line Data From Etokimab ECLIPSE Phase 2 Trial in Chronic Rhinosinusitis with Nasal Polyps Anticipated in First Half of 2020 Reported Positive Topline Data from Interim Analysis of GALLOP...
AnaptysBio to Present at The Cowen and Company 40th Annual Health Care Conference
February 25, 2020 16:00 ET
|
AnaptysBio, Inc.
SAN DIEGO, Feb. 25, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical...